This review evaluated the efficacy of light therapy in adults with mood disorders. The authors concluded that bright light therapy and dawn simulation for seasonal affective disorder and bright light therapy for non-seasonal depression show evidence of efficacy. It was not possible to determine the reliability of these conclusions since the review had some substantial methodological limitations.
Authors' objectives
To evaluate the efficacy of light therapy in treating mood disorders.
Searching
PubMed (January 1975 to July 2003 represented the main source of reference to identify relevant studies for the review; the search terms were reported. The search strategy was also applied to MEDLINE and the Cochrane Library (search dates not supplied). The bibliographies of reviews and other relevant papers were also screened. Only articles reported in the English language were included.
Study selection Study designs of evaluations included in the review
Placebo-controlled, randomised controlled trials (RCTs) were eligible for inclusion in the review.
Specific interventions included in the review
Studies that compared light therapy with a credible control were eligible for inclusion. Given the absence of standard definitions in the literature, the following inclusion criteria on dosing were applied: in studies of bright light treatment for seasonal affective disorder (SAD), there had to be a minimum of 4 days of at least 3,000 lux-hours, with comparison groups receiving a maximum of 300 lux; in studies of dawn simulation treatment, the intervention group needed to receive increasing light exposure from 0 to 200-300 lux over 1 to 2.5 hours, with comparison groups receiving an increase of less than 5 lux and/or less than 15 minutes in duration; studies of bright light used as adjunctive treatment had to meet the same criteria as that for bright light treatment of SAD.
A variety of treatment doses was found amongst the included studies and their duration ranged from 6 to 42 days.
Two reviewers independently assessed the eligibility of studies for inclusion in the review. Eligible studies were then data extracted in detail prior to a final decision by the two reviewers on whether to include them. Any disagreements were resolved by consensus.
Assessment of study quality
The authors did not state that they assessed validity.
Data extraction
The authors did not state how many reviewers performed the data extraction.
For each eligible study (where possible), the number of patients, along with a mean score and standard deviation on the psychiatric outcome measures, were extracted or calculated. These were then used to derive the standardised mean difference effect size (ES), along with 95% confidence interval (CI), and then adjusted for small sample size for each study. Authors were contacted, where necessary, for further data required for subsequent meta-analysis.
Methods of synthesis
How were the studies combined? The data were grouped into four categories according to disorder and treatment type: bright light for SAD; bright light for non-seasonal depression; dawn simulation for SAD; and, bright light as adjunctive treatment to antidepressant pharmacotherapy for non-seasonal depression. Pooled weighted ESs were calculated with 95% CI for each group, weighted using the inverse of variance method (a specific model was not mentioned). The pooled odds ratio (OR) and 95% CI were calculated to assess the effects on remission (defined as final Hamilton Depression Rating Scale score of 8 or less) from available data relating to bright light treatment of SAD. The method of pooling was not reported.
How were differences between studies investigated?
Where there were sufficient studies (the minimum number required was not reported), the Q test was used to assess the homogeneity of ESs across the studies. Results for the assessment of statistical heterogeneity were only reported for one of the four meta-analyses, although differences between the effects of treatment for other meta-analyses could be assessed by inspecting the forest plot. Where sufficient data were available, the Q test was also used to test the homogeneity of the ORs for the likelihood of remission.
